



This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Patient Group Direction (PGD)

For the administration or supply of

Phenylephrine Sterile eye drops 2.5%

By registered health care professionals for

For dilating the eye

Throughout the Manx Care and those contracted by the Manx Care where appropriate within practice

PGD NUMBER 104

1. Change history

Version number	Change details	Date
1	Original PGD ratified	June 2021

2. Medicines practice guideline 2: *Patient group directions*

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care [PGD website FAQs](#).

3. PGD development

Refer to the [NICE PGD competency framework for people developing PGDs](#)

Job Title & organisation	Name	Signature	Date
Author of the PGD			
Member of the PGD working group			

4. PGD authorisation

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job Title	Name	Signature	Date
Medical Director			
Chief Pharmacist/ Pharmaceutical Adviser			
Senior Paramedic			
Director of Nursing			
GP Adviser			
Senior Microbiologist (if PGD contains antimicrobials)			

5. PGD adoption by the provider

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job title and organisation	Signature	Date	Applicable or not applicable to area

6. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the [NICE PGD competency framework for health professionals using PGDs](#)

	Requirements of registered Healthcare professionals working under the PGD
Qualifications and professional registration	<ul style="list-style-type: none"> Registered healthcare professionals, working within or contracted by the Manx Care, GP practice or Hospice who are permitted staff groups outlined within the current PGD policy Pharmacists must be practising in Manx Care authorised premises i.e. contracted pharmacy premises
Initial training	<ul style="list-style-type: none"> Knowledge of current guidelines and the administration of the drug specified in this PGD/BNF and of the inclusion and exclusion criteria Training which enables the practitioner to make a clinical assessment to establish the need for the medication covered by this PGD Local training in the use of PGDs
Competency assessment	Staff will be assessed on their knowledge of drugs and clinical assessment as part the competency framework for registered health professionals using PGDs
Ongoing training and competency	The registered health care professionals should make sure they are aware of any changes to the recommendations for this medication; it is the responsibility of the registered health care professionals to keep up to date with continuing professional development. PGD updates will be held every two years

7. Clinical Conditions

Clinical condition or situation to which this PGD applies	To facilitate fundus examination and treatment in patients attending for assessment
Inclusion criteria	Patients over 16 years attending for fundus examination and treatment
Exclusion criteria	<ul style="list-style-type: none"> • Patients under 16 years • Pregnancy • Breastfeeding • Hypersensitivity of Phenylephrine • Patients with high hypermetropia (mydriasis may precipitate acute angle closure glaucoma) • Cardiac disease • Hypertension • Aneurysms • Thyrotoxicosis • Long-standing insulin dependent diabetes mellitus • Tachycardia • Narrow angle glaucoma (unless previously treatment with iridotomy) • Narrow angle prone to glaucoma precipitated by mydriatics • Patients on: <ul style="list-style-type: none"> ○ Mono-amine oxidase inhibitor (MAOIs) ○ Tricyclic anti-depressants ○ Anti-hypertensive agents (including beta-blockers)
Cautions (including any relevant action to be taken)	<ul style="list-style-type: none"> • Systematic absorption can be reduced by compressing the lacrimal sac at the medial canthus for a minute during and following the instillation of the drops • Discard contents of minims single dose until after one use • The use of the a drop of topical anaesthetic a few minutes before instillation of phenylephrine is recommended to prevent stinging • Discard contents on minims single dose unit after one use • On instillation and initial burning sensation may be experienced which may last up to 30 seconds • Blurring of vision – Individuals should be advised not to drive or operate hazardous machinery until normal vision is restored • Diabetes • Cerebral arteriosclerosis • Long-standing bronchial asthma • To reduce the risk of precipitating an attack of narrow angle glaucoma, evaluate the anterior chamber angle before use • Glaucoma/Suspected glaucoma • Transient in intraocular pressure
Arrangements for referral for medical advice	Patient should be referred to a more experienced clinical practitioner for further assessment

Action to be taken if patient excluded	Patient should be referred to a more experienced clinical practitioner for further assessment
Action to be taken if patient declines treatment	<ul style="list-style-type: none"> • A verbal explanation should be given to the patient on: the need for the medication and any possible effects or potential risks which may occur as a result of refusing treatment • This information must be documented in the patients' health records • Any patient who declines care must have demonstrated capacity to do so • Where appropriate care should be escalated

8. Details of the medicine

Name, form and strength of medicine	Phenylephrine 2.5% single use eye drops
Legal category	Prescription Only Medicine (POM)
Indicate any <u>off-label use</u> (if relevant)	None
Route/method of administration	Topical application to the eye/s
Dose and frequency	1 drop to the effected eye/s
Quantity to be administered and/or supplied	1 drop per procedure
Maximum or minimum treatment period	Up to 3 doses of 1 drop per procedure if eye/s are not adequately dilated
Storage	<ul style="list-style-type: none"> • Store at 2°C to 8°C. (Refrigerate. Do not freeze) • Do not expose to strong light • Each Minims Phenylephrine Eye Drop unit should be discarded after a single use
Adverse effects	<ul style="list-style-type: none"> • May cause stinging and transient blurring of vision • Patients should be advised not to drive or operate hazardous machinery until vision is clear • In some cases bright light can be uncomfortable for a few hours after receiving the drops • Rarely, more serious reactions, including spasm of the artery of the heart irregularities and heart attacks, have been reported after using phenylephrine solutions. These have usually occurred in patients using some 10 % phenylephrine and already suffering from heart disease • Occasionally allergic reactions or conjunctival sensitivity (abnormal sensitivity of the conjunctiva (thin, clear, moist membrane that coats the white outer surface of the eye) to various substances with discomfort upon instillation) • Can sometimes affect circulatory system, causing increased blood pressure and palpitations (a sensation in which a person is aware of an irregular, hard, or rapid heartbeat), tachycardia (fast heartbeats) and other heart irregularities (extrasystoles and cardiac arrhythmias)

Records to be kept	The administration of any medication given under a PGD must be recorded within the patient's medical records
---------------------------	--

9. Patient information

Verbal/Written information to be given to patient or carer	<ul style="list-style-type: none"> • On instillation an initial burning sensation may be experienced which may last up to 30 seconds • May cause transient blurring of vision on instillation. Warn patients not to drive or operate hazardous machinery until vision is clear • Verbal information must be given to patients and or carers for all medication being administered under a PGD • Where medication is being supplied under a PGD, written patient information leaflet must also be supplied • A patient information leaflet is available on request
Follow-up advice to be given to patient or carer	If symptoms do not improve or worsen or you become unwell, seek medical advice immediately

10. Appendix A

References
<ol style="list-style-type: none"> 1. British National Formulary (BNF) available online: https://bnf.nice.org.uk 2. Nursing and Midwifery (2018) "The code" available online: https://www.nmc.org.uk 3. Current Health Care Professions Council standards of practice 4. General Pharmaceutical Council standards 5. The General Optical Council 6. Electronic medicines compendium available online: https://www.medicines.org.uk

11. Appendix B

Health professionals agreed to practice
<ul style="list-style-type: none"> • Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor • A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves